Company profile: Tectonic Therapeutics
1.1 - Company Overview
Company description
- Provider of GPCR-targeted biologic drug discovery and development via its GEODe platform, with clinical programs including TX45, a therapeutic protein in Phase 1B trials for Group 2 Pulmonary Hypertension in heart failure with preserved ejection fraction, and an Fc-relaxin fusion targeting the RXFP1 receptor.
Products and services
- Fc-relaxin Fusion Program: A receptor-specific clinical program targeting the RXFP1 receptor to develop novel GPCR-targeted biologic therapies via Fc-relaxin fusion constructs
- GEODe™ Platform: A proprietary platform engineered to discover and develop biologic drugs targeting difficult G-protein Coupled Receptors (GPCRs), particularly those intractable to small-molecule approaches
- TX45: A clinical-stage therapeutic protein in Phase 1B trials for treating Group 2 Pulmonary Hypertension in patients with preserved ejection fraction heart failure
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tectonic Therapeutics
Checkmate Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on cancer immunotherapy, leveraging expertise in CpG oligonucleotides to discover and develop novel immunotherapies aimed at enabling more people with cancer to benefit from these treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Checkmate Pharmaceuticals company profile →
Monopar Therapeutics
HQ: United States
Website
- Description: Provider of orphan oncology therapeutics development, including MNPR-101-Zr, an imaging agent for MNPR-101 RIT in Phase 1 clinical trials; MNPR-101 RIT, a treatment for advanced solid cancers in late preclinical development; and drug candidates for solid cancers in early preclinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Monopar Therapeutics company profile →
Bright Peak Therapeutics
HQ: Switzerland
Website
- Description: Provider of immunotherapies for cancer and autoimmune diseases, enabling tissue- and cell-specific cytokine targeting with enhanced efficacy. Offerings include Bright Peak Immunoconjugates combining optimized cytokines with antibodies; a chemical protein synthesis platform for novel proteins; and candidates such as BPT567 (PD1-IL18), BPT331 (PD1-IL2), and BPT331CAPS (PD1-IL2CAPS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bright Peak Therapeutics company profile →
Tizona Therapeutics
HQ: United States
Website
- Description: Provider of next-generation immunotherapies, including TTX-080, an investigational antibody targeting HLA-G evaluated as monotherapy and in combination in patients with advanced cancers; TTX-030, a monoclonal antibody inhibiting CD39 studied with an approved anti-PD-1 agent and standard chemotherapy in adults with advanced cancer; and TZ-040, a pre-clinical program anticipated to enter IND-enabling studies targeting novel immuno-modulatory molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tizona Therapeutics company profile →
Opexa Therapeutics
HQ: United States
Website
- Description: Provider of patient-specific immunotherapies for the treatment of multiple sclerosis; its lead candidate, Tcelna, is a personalized T-cell immunotherapy in Phase IIb clinical development (the Abili-T trial).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Opexa Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tectonic Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tectonic Therapeutics
2.2 - Growth funds investing in similar companies to Tectonic Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tectonic Therapeutics
4.2 - Public trading comparable groups for Tectonic Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →